Researchers confirm IASLC proposed characterization of uncertain R Status R(un), prognosis between R0 and R1

UCLA researchers awarded $2.5M grant from BMS Foundation to increase lung cancer screening in underserved communities

A multidisciplinary team of experts in lung cancer screening and implementation science from the UCLA Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine at UCLA, and the UCLA Fielding School of Public Health, was awarded a $2.5 million grant from the Bristol Myers Squibb Foundation, an independent charitable organization, to spearhead a new initiative aimed at reducing disparities in lung cancer screening across Los Angeles County.

November 08, 2024

Vol.50 No.42

Cancer History Project Conversation with The Cancer Letter

Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer

On Nov. 24, 2003, an article in The Boston Globe told the story of a patient’s remarkable response to gefitinib, a drug that had recently been approved by FDA.

October 04, 2024

Vol.50 No.37

By Paul Goldberg and McKenzie Prillaman

Clinical Roundup

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.

September 13, 2024

Vol.50 No.34

Cancer History Project Conversation with The Cancer Letter

Lung cancer couldn’t slow down physician and athlete Lawrence Phillips

Something odd turned up in one of Lawrence Phillips’s routine health screenings in 2008.

September 06, 2024

Vol.50 No.33

By Deborah Doroshow and McKenzie Prillaman

Drugs & Targets

FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC

FDA granted priority review for Imfinzi (durvalumab), AstraZeneca’s supplemental Biologics License Application, based on the results from the positive ADRIATIC phase III trial in patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based concurrent chemoradiotherapy.

September 06, 2024

Vol.50 No.33

Drugs & Targets

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

Daiichi Sankyo and Merck have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug conjugates to include Merck’s MK-6070, an investigational delta-like ligand 3 targeting T-cell engager.

August 09, 2024

Vol.50 No.32

Researchers confirm IASLC proposed characterization of uncertain R Status R(un), prognosis between R0 and R1

YOU MAY BE INTERESTED IN

UCLA researchers awarded $2.5M grant from BMS Foundation to increase lung cancer screening in underserved communities

Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

Lung cancer couldn’t slow down physician and athlete Lawrence Phillips

FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

Renew today!

Subscriber content

Never miss an issue!

Login